Blog Profile / Pharmalot


URL :http://blogs.wsj.com/pharmalot/
Filed Under:Medical / Pharmaceutical
Posts on Regator:3599
Posts / Week:10.4
Archived Since:November 10, 2008

Blog Post Archive

Novo Nordisk Halts Sale of Tresiba Insulin in Germany Over Pricing Dispute

Novo Nordisk has decided to halt sales of its Tresiba insulin in Germany following a dispute with the National Association of Statutory Health Insurance Funds.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Glaxo, Research Fraud and Lots More!!

And so, another working week will soon draw to a close, at least on this side of the pond, where a holiday is just around the corner. As a result, we are getting an earlier-than-usual opportunity to daydream about weekend plans. Hooray!...Show More Summary

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Novartis, Taxes and Much More!!

Good morning, everyone, and how are you today? A spot of rain is descending on the Pharmalot campus, but our spirits remain as sunny as ever. As you may recall us noting previously, the Morning Mayor used to say that 'every brand new...Show More Summary

Hotel Workers Want to End Pharma Support of Continuing Medical Ed

A union that represents hotel workers has started a campaign to end pharmaceutical industry funding of continuing medical education.

How Much?! Feds Wants Novartis to pay $3.35B For Kickback Schemes

The U.S. Department of Justice says that Novartis should pay up to $3.35 billion in damages and civil fines for using kickbacks to boost sales of two drugs that caused federal health care programs to overpay for medicines.

Did Celgene Make the Right Move with its Juno Deal? What the Wags Say…

Celgene placed a big bet on a hot therapy that harnesses the immune system to fight cancer, by striking a deal with Juno Therapeutics, but the deal was greeted with a mix of enthusiasm and skepticism.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on AIDS, Roche and Lots More!!

Rise and shine, another busy day is on the way. A long-holiday weekend may be looming on this side of the pond, but we remain as engaged as ever in sorting out a never-ending stream of events. Of course, a few cups of stimulation make the task much easier. Show More Summary

Lilly is Fined by Brazil for ‘Sham’ Litigation Over a Cancer Drug Patent

Eli Lilly was fined $11 million by Brazilian authorities for pursuing “sham” patent litigation that was designed to extend exclusivity for its Gemzar cancer treatment.

FDA is Sued by Advocacy Groups That Want Gilead Hepatitis C Trial Data

A pair of public health advocacy organizations has filed a lawsuit against the FDA, claiming the agency failed to release clinical trial data for Gilead Sciences’ hepatitis C treatments on a timely basis.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on HIV, Gene ‘Editing’ and Lots More!!

Hello, everyone, and welcome to another working week, although this will be a short one on this side of the pond, due to the upcoming holiday. We are celebrating early, in fact, thanks to a bright, shiny sun and cool breeze to go with our ritual cup of stimulation. Show More Summary

Pfizer’s Fight Against Off-Patent Uses of Pregabalin Comes to Trial Monday

A closely watched legal battle on off-patent uses of prescription drugs is slated to come to trial in London on Monday.

Cash is not Always King in Pharma Pay-to-Delay Deals: Appeals Court

A federal appeals court has ruled that cash payments are not the only litmus test for determining whether a patent settlement between drug makers deserves antitrust scrutiny.

Celgene May Seek Sanctions Against Kyle Bass Over Patent Challenges

Celgene recently won permission from the U.S. Patent and Trademark Office to file a motion seeking sanctions against a Kyle Bass entity for allegedly abusing the process for reviewing patents.

Pharmalot.. Pharmalittle.. As the Weekend Nears: We’re Catching up on Bristol, Sanofi and Much More!!

And so, another working week will soon draw to a close. This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is reasonably modest. We hope to spend time with our short people, catch up on our reading and maybe watch a moving picture or two. Show More Summary

21st Century Cures Bill to Cost $869M for Rare Disease Drug Marketing

A provision of the 21st Century Cures bill that would grant six-month extra marketing exclusivity to existing drugs that win approval to treat rare diseases would cost the federal government $869 million over the next decade.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Meningitis B, Parexel and Lots More!!

Rise and shine, folks, another busy day is on the way. Summertime may have officially arrived this week, but the trusty to-do list remains as long as ever. No doubt, you can relate. After all, the world continues to spin, yes? Well, at least for a little while longer. Show More Summary

Viagra May Not Cause Melanoma, but the ‘Viagra Lifestyle’ May be a Problem

A new study finds that taking several erectile dysfunction drugs may, indeed, pose a modest, but statistically significant increased risk of developing the cancer, but a cause-and-effect relationship remains unclear.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on AstraZeneca, Marijuana and Lots More!!

Good morning, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? While you ponder the possibilities, we will celebrate a gorgeous morning with some needed cups of stimulation. After the heat and humidity of the past few days, a sparkling sun and coooool breeze are quite welcome. Show More Summary

Next Time an FDA Inspector Visits, Make Sure Everything is Dusted

Be sure to do some dusting the next time an FDA inspector visits your manufacturing facility.

Copyright © 2015 Regator, LLC